September 2022

The Lancet

PURE: Metabolic, behavioural, and psychosocial risk factors and cardiovascular disease in women compared with men in 21 high-income, middle-income, and low-income countries: an analysis

M Walli-Attaei, A Rosengren, S Rangarajan, Y Breet, S Abdul-Razak, W Al Sharief, KF Alhabib, A Avezum, J Chifamba, R Diaz, R Gupta, B Hu, R Iqbal, R Ismail, R Kelishadi, R Khatib, X Lang, S Li, P Lopez-Jaramillo, V Mohan, A Oguz, LM Palileo-Villanueva, K Poltyn-Zaradna, PR Sreelakshmi, LVM Pinnaka, P Seron, K Teo, ST Verghese, A Wielgosz, K Yeates, R Yusuf, SS Anand, S Yusuf

Read More

September 2022

The Lancet

PACIFIC-Stroke: Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke – an international, randomised, double-blind, placebo-controlled, phase 2b trial

A Shoamanesh, H Mundi, EE Smith, J Masjuan, I Milanov, T Hirano, A Agafina, B Campbell, V Caso, JL Mas, Dong, P Turcani, H Christensen, JM Ferro, R Veltkamp, R Mikulik, GM De Marchis, T Robinson, R Lemmens, A Stepien, S Greisenegger, R Roine, L Csiba, P Khatri, J Coutinho, AG Lindgren, AM Demchuk, P Colorado, B Kirsch, C Neumann, L Heenan, L Xu, SJ Connolly, RG Hart

Read More

August 2022

The New England Journal of Medicine (NEJM)

INVICTUS: Rivaroxaban in rheumatic heart disease–associated atrial fibrillation

SJ Connolly, G Karthikeyan, M Ntsekhe, A Haileamlak, A El Sayed, A El Ghamrawy, A Damasceno, A Avezum, AML Dans, B Gitura, D Hu, ER Kamanzi, F Maklady, G Fana, JA Gonzalez-Hermosillo, J Musuku, K Kazmi, L Zuhlke, L Gondwe, C Ma, M Paniagua, OS Ogah, OJ Molef-Baikai, P Lwabi, P Chillo, SK Sharma, TTJ Cabral, WM Tarhuni, A Benz, M van Eikels, A Krol, D Pattath, K Balasubramanian, S Rangarajan, C Ramasundarahettige, B Mayosi, S Yusuf

Read More

Back To Top